Entrectinib is a type of targeted therapy used to treat certain types of cancer. It is a small molecule inhibitor that works by blocking the activity of certain proteins that help cancer cells survive and grow. Entrectinib is approved to treat non-small cell lung cancer (NSCLC), and certain types of advanced solid tumors that have a rearrangement of NTRK genes. It is taken orally, typically once daily. Common side effects of entrectinib include diarrhea, fatigue, nausea, dizziness, and constipation.
Entrectinib is a targeted therapy medication used to treat specific types of cancers with certain genetic mutations. Here's a breakdown of what we know about Entrectinib:
Function:
- Entrectinib is a kinase inhibitor. Kinases are enzymes that play a crucial role in cell signaling pathways. By inhibiting specific kinases, Entrectinib can disrupt the growth and spread of cancer cells.
Targeted Cancers:
Entrectinib is effective against tumors with mutations in genes that code for proteins involved in these signaling pathways, particularly:
- NTRK genes: Mutations in these genes can lead to the production of abnormal proteins that drive cancer cell growth. Entrectinib targets these abnormal proteins.
- ROS1 gene: Mutations in this gene can also contribute to cancer development. Entrectinib can block the activity of the ROS1 protein.
Current Use:
Entrectinib is a relatively new medication that has received approval for specific cancer types based on the presence of these genetic mutations. Here are some examples:
- Non-small cell lung cancer (NSCLC): Entrectinib is approved for adults and children with advanced (metastatic) NSCLC harboring NTRK fusion mutations.
- Colorectal cancer: It's approved for adults with metastatic colorectal cancer with a ROS1 mutation that has progressed after other treatments.
- Other cancers: Clinical trials are ongoing to investigate Entrectinib's efficacy in other cancer types with these mutations.
Administration:
Entrectinib is typically administered orally, usually as capsules taken once daily.
Important Considerations:
- Entrectinib is a targeted therapy, and its effectiveness depends on the presence of the specific mutations it targets. Genetic testing is necessary to determine if a patient is a candidate for Entrectinib treatment.
- Entrectinib can cause side effects, including fatigue, constipation, diarrhea, dry mouth, dizziness, and peripheral neuropathy (tingling or numbness in hands and feet).
- It may interact with other medications, so it's crucial to disclose your complete medical history and current medications to your doctor.
Here are some additional points to remember:
- This information is intended for general knowledge and shouldn't replace consulting a healthcare professional.
- Entrectinib is a promising new therapy for specific cancers with certain genetic mutations.
- If you have been diagnosed with cancer, your doctor will determine if genetic testing for these mutations is appropriate and discuss Entrectinib as a potential treatment option if the results are positive.